Biodesix touts VeriStrat test results

2019 09 09 20 46 2283 Lung Cancer 400

At the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer on August 8 in Vienna, Biodesix will present results showing that its VeriStrat liquid biopsy test can predict survival in patients with non-small cell lung cancer.

The blood-based test was predictive of progression-free survival and overall survival in patients with non-small cell lung cancer with low or negative PD-L1 treated with immune checkpoint inhibitors, the firm said.

Patients whose VeriStrat status results were VeriStrat Good had significantly greater progression-free survival and overall survival compared to the patients whose status was VeriStrat Poor, according to the company.

The test uses a proteomic signature identified using MALDI-ToF mass spectrometry coupled with machine learning.

Page 1 of 4
Next Page